News
Homepage
/
News
/
In 2023
/
SST Corporation and Viwit Pharmaceuticals Establish Strategic Collaboration

News classification

Check category

News Center

Viwit’s Levetiracetam Tablets Approved by FDA 2024-04-09 11:28:41
On April 5, 2024, Viwit Pharmaceuticals' Levetiracetam Tablets received an Approval Letter (#078869) from the U.S. Food and Drug Administration (FDA), marking Viwit's first approved oral solid dosage in the United States.
Viwit Pharmaceuticals' Mirabegron API Receives Official Approval by China NMPA 2024-01-26 11:09:29
On January 23, 2024, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for its own proprietary active pharmaceutical ingredient (API) Mirabegron, developed independently. The issued registration number is Y20220000096, and the corresponding notice number is 2024YS00039.
Viwit Pharmaceuticals' Vildagliptin Tablets Receive Official Approval by China NMPA 2023-12-22 13:19:44
Viwit Pharmaceuticals is pleased to announce the acquisition of the Drug Registration Certificate (Certificate No: 2023S01974) from the National Medical Products Administration (NMPA) for a proprietary finished dosage form, Vildagliptin tablet. This signifies the official approval of this product in the Chinese market.
Viwit Pharmaceuticals' Lidocaine Injection Receives Official Approval by China NMPA 2023-12-19 11:25:05
On December 18, 2023, Viwit Pharmaceuticals received the "Drug Supplementary Application Approval Notice" (Notice No: 2023B06224) issued by the China National Medical Products Administration for a proprietary finished dosage form, Lidocaine Hydrochloride for Injection (5ml: 0.1g).
Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA 2023-12-07 08:31:28
On November 30, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA) for its independently developed active pharmaceutical ingredient (API), Vildagliptin. The registration number is Y20210000619, and the notice number is 2023YS00803.
Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA 2023-10-31 15:33:57
On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.

SST Corporation and Viwit Pharmaceuticals Establish Strategic Collaboration

  • Categories:In 2023
  • Author:
  • Origin:
  • Time of issue:2023-08-11 11:23

(Summary description)Having become an officially qualified API/CMC supplier to SST Corporation, Viwit and SST have established a strategic collaboration aiming to promote small molecule pharmaceutical contract development and manufacturing organization (CDMO) services in North America.

SST Corporation and Viwit Pharmaceuticals Establish Strategic Collaboration

(Summary description)Having become an officially qualified API/CMC supplier to SST Corporation, Viwit and SST have established a strategic collaboration aiming to promote small molecule pharmaceutical contract development and manufacturing organization (CDMO) services in North America.

  • Categories:In 2023
  • Author:
  • Origin:
  • Time of issue:2023-08-11 11:23
  • Views:
Information

SST Corporation and Viwit Pharmaceuticals Establish Strategic Collaboration for the Promotion of Generic APIs and CDMO Services

Having become an officially qualified API/CMC supplier to SST Corporation, Viwit and SST have established a strategic collaboration aiming to promote small molecule pharmaceutical contract development and manufacturing organization (CDMO) services in North America. This collaboration not only initiates a new business offering for SST but will also attract a broader audience for Viwit. Congratulations on the collaboration and bright futures for both companies.

About Viwit Pharmaceuticals

Viwit Pharma is a fast-growing research-based pharmaceutical company. Equipped with strong development technology, 600+ elite process development scientists and chemical engineers, as well as outstanding 820,000+ ft2 cGMP manufacturing capability, Viwit serves as a desired CDMO/CMO partner for 1400 + biotechnology and pharmaceutical companies worldwide. We support the development and manufacturing of key starting materials, advanced intermediates, small molecule and peptide drug substances, and drug products with a variety of therapeutic indications from laboratory batches to clinical I/II/III and commercial supply. We are specialized in a variety of chemical reactions including but not limited to Hazardous Chemistry (Borane, Bromination, Fluorination), Asymmetric Reduction/Hydrogenation/Synthesis, Cryogenic Reaction, Suzuki Coupling, Grignard Reaction, etc.

About SST Corporation

SST Corporation was founded in New York City in 1948, as a brokerage house for industrial chemical supplies and Active Pharmaceutical Ingredients. Since its inception, SST has represented many international suppliers and provided them entry to the North American marketplace.  As SST enters its 8th decade in business, we continue to evolve in parallel to new developments in the market to meet the changing needs of our customers and suppliers. Our customer base ranges from the biggest generic pharmaceutical companies in the world to niche 505B2 innovators and small startup organizations.  Our supplier base encompasses high-quality manufacturers from around the world.

 

Contacts

 

SST Corporation                                                

Joe Leone

Executive VP

973-473-4300

jleone@sst-corp.com

 

Viwit Pharmaceuticals

Jasmine Lu

General Manager, US

732-421-5655

jasmine.lu@viwit.com

Scan the QR code to read on your phone

Previous: Meeting Viwit Pharmaceuticals at CPHI Barcelona
Next: Viwit Pharmaceutical Invites You to Meet at CPHI North America
Previous: Meeting Viwit Pharmaceuticals at CPHI Barcelona
Next: Viwit Pharmaceutical Invites You to Meet at CPHI North America
search
Confirm
Close
About Us
Company Introduction Corporate History Business Introduction Corporate Governance Company Culture Corporate Honors Viwit Family Media Center Video
R&D and Innovation
R&D Innovation Product Pipeline Achievements
Products
Drug Products Biologics APIs Intermediates Boranes OLED Materials
Innovation
CDMO Project Collaboration In-/Out-Licensing Joint Venture
Sustainable
EHS Energy Quality Supplier
News Center
In 2024 In 2023 In 2022 In 2021 In 2020 In 2019 In 2018 In 2017 In 2016
Join Us
Talent Philosophy Talent Development Salary and Benefits Campus Recruiting Social Recruitment
Contact Us
Online Message Contact Us
News Center
dp EN
dp 中文

wz

wz